Coherent Launches ACE FL, an All-New, Two-Micron Fiber Laser to Address the Expanding Opportunities in Urology and Other Medical Markets
Coherent (NYSE:COHR) has launched the ACE FL series, a new thulium fiber laser (TFL) designed for medical applications, particularly lithotripsy and benign prostatic hyperplasia (BPH) treatment. The two-micron system offers enhanced precision, better patient outcomes, and improved efficiency compared to traditional holmium:YAG systems.
The ACE FL platform features proprietary fiber designs, superior cutting precision, compact form factor, and enhanced energy efficiency. The system is optimized for integration into surgical devices used in minimally invasive procedures and is complemented by Coherent's range of disposable fiber assemblies.
Coherent (NYSE:COHR) ha lanciato la serie ACE FL, un nuovo laser a fibra di tulio (TFL) progettato per applicazioni mediche, in particolare per la litotripsia e il trattamento dell'iperplasia prostatica benigna (BPH). Il sistema a due micron offre una precisione migliorata, risultati clinici superiori e una maggiore efficienza rispetto ai tradizionali sistemi al holmio:YAG.
La piattaforma ACE FL presenta design proprietari delle fibre, una precisione di taglio superiore, un formato compatto e una maggiore efficienza energetica. Il sistema è ottimizzato per l'integrazione in dispositivi chirurgici utilizzati in procedure minimamente invasive ed è supportato dalla gamma di assemblaggi di fibre monouso di Coherent.
Coherent (NYSE:COHR) ha lanzado la serie ACE FL, un nuevo láser de fibra de tulio (TFL) diseñado para aplicaciones médicas, especialmente para litotricia y tratamiento de hiperplasia prostática benigna (HPB). El sistema de dos micrones ofrece mayor precisión, mejores resultados para los pacientes y una eficiencia mejorada en comparación con los sistemas tradicionales de holmio:YAG.
La plataforma ACE FL cuenta con diseños de fibra patentados, una precisión de corte superior, un formato compacto y una eficiencia energética mejorada. El sistema está optimizado para su integración en dispositivos quirúrgicos utilizados en procedimientos mínimamente invasivos y se complementa con la gama de ensamblajes de fibra desechables de Coherent.
Coherent (NYSE:COHR)는 의료용으로 설계된 새로운 툴륨 섬유 레이저(TFL)인 ACE FL 시리즈를 출시했습니다. 이 시스템은 특히 요로결석 분쇄술과 양성 전립선 비대증(BPH) 치료에 적합합니다. 2마이크론 시스템은 기존의 홀뮴:YAG 시스템에 비해 향상된 정밀도, 더 나은 환자 결과 및 효율성을 제공합니다.
ACE FL 플랫폼은 독자적인 섬유 설계, 우수한 절단 정밀도, 컴팩트한 폼 팩터 및 향상된 에너지 효율성을 특징으로 합니다. 이 시스템은 최소 침습 수술에 사용되는 수술 기기에 통합되도록 최적화되어 있으며, Coherent의 일회용 섬유 조립체와 함께 제공됩니다.
Coherent (NYSE:COHR) a lancé la série ACE FL, un nouveau laser à fibre de thulium (TFL) conçu pour des applications médicales, notamment la lithotripsie et le traitement de l'hyperplasie bénigne de la prostate (HBP). Ce système à deux microns offre une précision accrue, de meilleurs résultats pour les patients et une efficacité améliorée par rapport aux systèmes traditionnels au holmium:YAG.
La plateforme ACE FL présente des conceptions de fibres propriétaires, une précision de coupe supérieure, un format compact et une meilleure efficacité énergétique. Le système est optimisé pour une intégration dans des dispositifs chirurgicaux utilisés lors de procédures peu invasives et est complété par la gamme d'assemblages de fibres jetables de Coherent.
Coherent (NYSE:COHR) hat die ACE FL-Serie vorgestellt, einen neuen Thulium-Faserlaser (TFL), der für medizinische Anwendungen entwickelt wurde, insbesondere für Lithotripsie und die Behandlung der benignen Prostatahyperplasie (BPH). Das Zwei-Mikrometer-System bietet im Vergleich zu herkömmlichen Holmium:YAG-Systemen eine verbesserte Präzision, bessere Patientenergebnisse und eine höhere Effizienz.
Die ACE FL-Plattform verfügt über proprietäre Faserdesigns, überlegene Schneidpräzision, ein kompaktes Format und verbesserte Energieeffizienz. Das System ist für die Integration in chirurgische Geräte für minimalinvasive Verfahren optimiert und wird durch Coherents Sortiment an Einweg-Faserbaugruppen ergänzt.
- New ACE FL platform offers superior precision and improved patient outcomes
- Product targets expanding market opportunities in urology and medical applications
- Enhanced energy efficiency through lower power consumption
- Vertically integrated manufacturing ensures reliable supply chain
- Proprietary fiber designs protected by IP
- None.
Insights
Coherent's new thulium fiber laser brings significant technical advantages over legacy systems for urological procedures with strong market potential.
Coherent's ACE FL thulium fiber laser represents a meaningful technological advancement over traditional holmium:YAG lasers used in urological procedures. The two-micron wavelength is particularly efficient for tissue ablation and stone fragmentation, which translates to tangible clinical benefits in lithotripsy and BPH treatment.
The technical superiority lies in several key areas: the laser's wavelength is better absorbed by water and tissue, enabling more precise cutting with less thermal damage during BPH enucleation procedures. For lithotripsy, this precision means more efficient stone fragmentation with potentially reduced procedural time and complications.
From an engineering perspective, fiber lasers offer substantial advantages in size, reliability and energy efficiency compared to solid-state alternatives. The compact form factor makes integration into existing surgical systems more straightforward for OEM partners, while lower power consumption and improved thermal management reduce operational costs and enhance device longevity.
The clinical value proposition is compelling - minimally invasive procedures using superior laser technology can potentially reduce recovery times, complications, and hospital stays. The bundling with disposable fiber assemblies creates a recurring revenue component beyond the initial system sale, following the razor-blade business model common in medical devices.
The launch of Coherent's ACE FL series positions the company strategically in the rapidly growing urological device market, which is projected to expand at
Coherent's vertical integration in fiber manufacturing represents a significant competitive advantage. By controlling the entire supply chain from proprietary fiber designs through final assembly, the company can maintain quality control while potentially achieving higher margins than competitors who rely on third-party components.
The business model shows sophisticated planning - by pairing capital equipment (the laser system) with proprietary disposable fiber assemblies, Coherent creates a recurring revenue stream that could stabilize cash flows beyond initial system sales. This approach mirrors successful models in adjacent medical technology markets.
The timing is opportune as healthcare systems globally push toward outpatient procedures to reduce costs. The ACE FL's efficiency advantages align perfectly with this macro trend, potentially accelerating adoption in ambulatory surgery centers and outpatient departments.
While the press release doesn't provide specific revenue projections, this launch addresses a specialized but lucrative market. The emphasis on OEM partnerships suggests Coherent is leveraging its technological expertise while letting established medical device companies handle distribution and clinical relationships - a capital-efficient go-to-market strategy.
SAXONBURG, Pa., June 24, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of its ACE FL series, thulium fiber laser (TFL), engineered specifically for therapeutic medical applications – most notably for lithotripsy and benign prostatic hyperplasia (BPH) treatment.
The new two-micron ACE FL system delivers superior precision, improved patient outcomes, and enhanced procedural efficiency compared to legacy laser technologies such as holmium:YAG systems. It is optimized for integration into surgical devices and laser systems used in minimally invasive procedures.
“Our new thulium fiber laser is a breakthrough platform that enables medical OEMs to deliver safer, faster, and more effective treatments for kidney stones and BPH,” said Martin Seifert, Vice President, High-Power Fiber Laser Business Unit at Coherent. “With the growing shift toward outpatient and minimally invasive procedures, the market opportunity for fiber-based surgical lasers is stronger than ever.”
Thulium fiber lasers offer superior cutting precision in BPH enucleation, a compact form factor ideal for OEM integration, and enhanced energy efficiency through lower power consumption and improved thermal management.
The ACE FL platform leverages proprietary fiber designs and manufacturing capabilities to offer OEM partners a scalable, high-performance solution for next-generation surgical tools. In addition, Coherent enhances rapid ease of integration by multiplying the power of our new ACE FL series with the surgically proven capabilities of our superb range of disposable fiber assemblies.
With vertically integrated manufacturing and IP-protected fiber designs, Coherent is uniquely positioned to support global medical device manufacturers with reliable supply and long-term innovation.
Coherent will showcase the ACE FL at LASER World of Photonics Munich 2025.
About Coherent
Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver innovations that resonate with our customers in diversified applications for the industrial, communications, electronics, and instrumentation markets. Coherent has research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, please visit us at coherent.com.
Media Contact:
innovations@coherent.com
FAQ
What is Coherent's new ACE FL fiber laser used for?
How does Coherent's ACE FL compare to traditional laser systems?
What are the key advantages of Coherent's new ACE FL laser system?
When will Coherent (COHR) showcase the new ACE FL laser?
What markets is Coherent targeting with the ACE FL laser?
